Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Different graft-vs-host disease prophylaxis strategy for allogeneic hematopoietic stem cell transplantation in adults with chronic active EBV infection

Min Liu, Qiuxia Yu, Yang Cao, Jia Wei, Yaxian Ma, Zetong Hong, Qing Yin, Yan Feng, ZhaoYang Hong, Tongjuan Li, Jia Gu, Liting Chen, Yicheng Zhang, Miao Zheng

Blood (2025) 146 (Supplement 1): 7758.

https://doi.org/10.1182/blood-2025-7758

Published: 2025

Journal Articles

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

Yi Zhu, Xiwen Tong, Bin Xu, Shiyuan Zhang, Andie Fu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2025-6989

Published: 2025

Journal Articles

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Li Li, Andie Fu, Xiwen Tong, Bin Xu, Xia Mao, Ying Wang, Shiyuan Zhang, Yi Zhu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2025-5863

Published: 2025

Journal Articles

CRE intestinal colonization correlates with increased progression risk following CAR T cell therapy in relapsed/refractory lymphoma

Qing Yin, Yaxian Ma, Zetong Hong, Yan Feng, Min Liu, Tongjuan Li, Jia Wei, Miao Zheng

Blood (2025) 146 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2025-1939

Published: 2025

Journal Articles

Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study

Jie Zhao, Linyu Li, Zhilin Gao, Shaolong He, Lifang Huang, Tao Wang, Rong Gong, Qiujuan Zhu, Xize Wang, Jia Wei, Weiwei Tian

Blood (2025) 146 (Supplement 1): 253.

https://doi.org/10.1182/blood-2025-253

Published: 2025

Journal Articles

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Jia Chen, Yongrong Lai, Xiaowen Zhai, Wei Li Zhao, Rongrong Liu, Xiaowen Qian, Wei Tang, Lijie Wang, Xu-Kai Ma, Yaliang Li, Jia Wei, Kewei Lan, Yan Zhang, Li Yang, Xiaodun (Susan) Mou

Blood (2025) 146 (Supplement 1): 6090.

https://doi.org/10.1182/blood-2025-6090

Published: 2025

Journal Articles

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Wei Mu, Anqi Zhang, Xingcheng Yang, Xiaoxi Zhou, Jie Zhao, Yicheng Zhang, Weiwei Tian, Junjie Shen, Haoyue Qin, Yingzi Zhang, Cheng Qian, Jia Wei

Blood (2025) 146 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2025-1639

Published: 2025

Journal Articles

Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML

Xingcheng Yang, Juan Peng, Ling Ma, Lei Zhang, Yicheng Zhang, Xia Mao, Jue Wang, Jia Wei

Blood (2025) 146 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2025-1693

Published: 2025

Journal Articles

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Shiyuan Zhang, Shuai Su, Bin Xu, Xiwen Tong, Yi Zhu, Andie Fu, Zhuoxin Wen, Zhiqiong Wang, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2025-1673

Published: 2025

Journal Articles

Mechanism and therapeutic efficacy of the XPO1 inhibitor selinexor in refractory/relapsed EBV-positive NK cell lymphoma

Yaxian Ma, Yuhan Bao, Min Liu, Tongjuan Li, Qing Yin, Zetong Hong, Yan Feng, Jia Wei, Miao Zheng

Blood (2025) 146 (Supplement 1): 7174.

https://doi.org/10.1182/blood-2025-7174

Published: 2025

Journal Articles

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang, Xiaoying Zhang, Xingcheng Yang, Juan Peng, Jiaqi Guo, Liting Chen, Hui Luo, Li Zhu, Xiaoxi Zhou, Yang Yang, Na Wang, Jue Wang, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2025-4115

Published: 2025

Journal Articles

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

Xiaoying Zhang, Jue Wang, Na Wang, Jia Wei, Yang Cao, Yicheng Zhang

Blood (2025) 146 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2025-7243

Published: 2025

Journal Articles

Efficacy and safety of Daratumumab in relapse/refractory diffuse large B-cell lymphoma

Zetong Hong, ZhaoYang Hong, Tongjuan Li, Yaxian Ma, Min Liu, Qing Yin, Wei Huang, Kuangguo Zhou, Dan Li, Yan Feng, Jia Wei, Miao Zheng

Blood (2025) 146 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2025-7225

Published: 2025

Journal Articles

The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.

Tao Wang, Jia Wei, Liangming Ma

Blood (2025) 146 (Supplement 1): 5986.

https://doi.org/10.1182/blood-2025-5986

Published: 2025

Journal Articles

TDI01 in the treatment of moderate to severe chronic graft-versus-host disease: Updated results from a multicenter, OPEN-label phase IB/II study (An Update)

Xiaojun Huang, Xiao-Dong Mo, Xuejun Zhang, Rong Guo, Er-Lie Jiang, Jiejing Qian, Xiaoyu Zhu, Jia Wei, Shun-Qing Wang, Zhongming Zhang, Zhuogang Liu, Yuxian Huang, Zhiguo Wang, Xiaoyuan Dong, Hai Yi, Ying Li

Blood (2025) 146 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2025-4229

Published: 2025

Journal Articles

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Juan Peng, Zekai Mao, Yang Cao, Na Wang, Jue Wang, Yang Yang, Jinghuan Xu, Fankai Meng, Liting Chen, Xia Mao, Jiaqi Guo, Xiaoxi Zhou, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2025-3712

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

T cell-derived TNF-α mediates myelofibrosis via JAK2/STAT3-ADAM17 axis in JAK2V617F⁺ myeloproliferative neoplasms

Zhuming Yang, Zhenhao Wang, Jia Wei, Zhenya Hong

Blood (2025) 146 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2025-1985

Published: 2025

Journal Articles

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Shiyuan Zhang, Longlong Liu, Bin Xu, Xiwen Tong, Andie Fu, Shuai Su, Yi Zhu, Zhuoxin Wen, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2025-7016

Published: 2025

Journal Articles

CD19 CAR-T cell therapy in AML1-ETO positive Acute Myeloid Leukemia: A multi-omics analysis of response determinants

Anqi Zhang, Jie Zhao, Yicheng Zhang, Weiwei Tian, Wei Mu, Jia Wei

Blood (2025) 146 (Supplement 1): 6957.

https://doi.org/10.1182/blood-2025-6957

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Different graft-vs-host disease prophylaxis strategy for allogeneic hematopoietic stem cell transplantation in adults with chronic active EBV infection

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

CRE intestinal colonization correlates with increased progression risk following CAR T cell therapy in relapsed/refractory lymphoma

Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Mechanism and therapeutic efficacy of the XPO1 inhibitor selinexor in refractory/relapsed EBV-positive NK cell lymphoma

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

Efficacy and safety of Daratumumab in relapse/refractory diffuse large B-cell lymphoma

The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.

TDI01 in the treatment of moderate to severe chronic graft-versus-host disease: Updated results from a multicenter, OPEN-label phase IB/II study (An Update)

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

T cell-derived TNF-α mediates myelofibrosis via JAK2/STAT3-ADAM17 axis in JAK2V617F⁺ myeloproliferative neoplasms

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

CD19 CAR-T cell therapy in AML1-ETO positive Acute Myeloid Leukemia: A multi-omics analysis of response determinants

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only